Real-World Data on First Relapse in Multiple Myeloma: Treatment Patterns and Outcomes in Finland Using Automated Data Collection
Acta Haematologica · 12.06.2026 · 1-12
DOI: 10.1159/000552684 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 12.06.2026. Verfasst von Johanna Vikkula und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medaffcon Oy, Espoo, Finland. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
This study aimed to characterize multiple myeloma (MM) patients at the first relapse and examine treatment outcomes.
Methods
This registry-based retrospective study examined relapsed MM patients in two Finnish Wellbeing Services Counties (Helsinki and Uusimaa, and Southwest Finland) from 2013 to 2022. Relapse was identified per current guidelines using serum paraprotein, plasma immunoglobulins, and free light chain data. Data were collected from hospital data lakes, Social Insurance Institution and Digital and Population Services Agency. Patients were stratified by age (≤70 vs. >70), index year, and time to first relapse (≤2 vs. >2 years post-diagnosis).
Results
Of 1,221 patients treated for MM between 2012 and 2022, 286 met the study inclusion criteria. Median overall survival from the relapse was higher in the younger patients (32.4 months vs. 20.0 months). In the first half of follow-up, lenalidomide was the most common pharmacotherapy in both age groups. After 2018, CD38-based treatments and pomalidomide increased significantly for younger patients, remaining limited in the elderly.
Conclusion
While new therapies have been adopted for younger MM patients, the treatment of older patients at first relapse has had little change. Given their poorer outcomes, there is a need to improve care for older MM patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medaffcon Oy, Espoo, Finland.
- Turku University, Turku, Finland.
- Medaffcon Oy, Espoo, Finland, outi.laatikainen@medaffcon.com.
- GSK Oy, Helsinki, Finland.
- Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, Finland.
Zitieren
APA
Vikkula, J., Remes, K., Laatikainen, O., Utriainen, M., Tikka, S., & Lievonen, J. (2026). Real-World Data on First Relapse in Multiple Myeloma: Treatment Patterns and Outcomes in Finland Using Automated Data Collection. Acta Haematologica, 1-12. https://doi.org/10.1159/000552684
Vancouver
Vikkula J, Remes K, Laatikainen O, Utriainen M, Tikka S, Lievonen J. Real-World Data on First Relapse in Multiple Myeloma: Treatment Patterns and Outcomes in Finland Using Automated Data Collection. Acta Haematologica. 2026:1-12. doi:10.1159/000552684
BibTeX
@article{Vikkula2026,
author = {Vikkula, Johanna and Remes, Kari and Laatikainen, Outi and Utriainen, Merja and Tikka, Saara and Lievonen, Juha},
title = {Real-World Data on First Relapse in Multiple Myeloma: Treatment Patterns and Outcomes in Finland Using Automated Data Collection},
journal = {Acta Haematologica},
year = {2026},
pages = {1--12},
doi = {10.1159/000552684}
}
EUVIMED